Login to Your Account

Samsung's biosimilar push wins with Flixabi recommendation in EU

By Cornelia Zou
Staff Writer

Tuesday, April 5, 2016

HONG KONG – South Korea's Samsung Bioepis Co. Ltd. has taken another step forward in its push to market biosimilars globally having received positive feedback from the EMA for its biosimilar to Remicade (infliximab, Janssen Biotech Inc.). The company is now expecting an approval soon.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription